Large-scale trials of a coronavirus vaccine candidate produced by Pfizer/BioNTech has revealed that it is 90% effective, said the manufacturer in a statement.
In what is being considered as possibly the biggest news regarding the virus ever since it originated, the vaccine’s effectiveness can mean it can hit the markets for treatment by the year’s end in some countries of the world.
The study shows that people who received two doses as part of the trial observed 90% fewer symptomatic cases of Covid-19 than participants who were given a placebo.
“Today is a great day for science and humanity. The first set of results from our phase 3 Covid-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent Covid-19,” said Dr. Albert Bourla, the Pfizer chairman and chief executive.